Molecular structure of LY2603618, CAS Number: 911222-45-2
LY2603618 (CAS 911222-45-2)
Alternate Names:
(S)-1-(5-bromo-4-methyl-2-(morpholin-2-ylmethoxy)phenyl)-3-(5-methylpyrazin-2-yl)urea
Application:
LY2603618 is a selective Chk1 inhibitor
CAS Number:
911222-45-2
Purity:
≥98%
Molecular Weight:
436.30
Molecular Formula:
C18H22BrN5O3
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
LY2603618 (IC-83) is a very selective Chk1 (checkpoint kinase 1) inhibitor with the potential for antitumor effects. Chk1 is an ATP-dependent serine-threonine kinase that is very important to the checkpoint monitoring system of DNA replication. LY2603618 is a member of the family of tyrosine kinase inhibitors. Tyrosine kinases are enzymes that are involved in the signaling pathways that control cell growth. Studies have found anti-inflammatory, anti-angiogenic, and anti-cancer properties of LY2603618. In vitro studies have shown it to be effective in inhibiting the growth of prostate and lung cancer cells.
LY2603618 (CAS 911222-45-2) References
- PARP and CHK inhibitors interact to cause DNA damage and cell death in mammary carcinoma cells. | Booth, L., et al. 2013. Cancer Biol Ther. 14: 458-65. PMID: 23917378
- Panobinostat synergistically enhances the cytotoxic effects of cisplatin, doxorubicin or etoposide on high-risk neuroblastoma cells. | Wang, G., et al. 2013. PLoS One. 8: e76662. PMID: 24098799
- Characterization and preclinical development of LY2603618: a selective and potent Chk1 inhibitor. | King, C., et al. 2014. Invest New Drugs. 32: 213-26. PMID: 24114124
- The checkpoint 1 kinase inhibitor LY2603618 induces cell cycle arrest, DNA damage response and autophagy in cancer cells. | Wang, FZ., et al. 2014. Apoptosis. 19: 1389-98. PMID: 24928205
- LY2603618, a selective CHK1 inhibitor, enhances the anti-tumor effect of gemcitabine in xenograft tumor models. | Barnard, D., et al. 2016. Invest New Drugs. 34: 49-60. PMID: 26612134
- Inhibition of CHK1 enhances cell death induced by the Bcl-2-selective inhibitor ABT-199 in acute myeloid leukemia cells. | Zhao, J., et al. 2016. Oncotarget. 7: 34785-99. PMID: 27166183
- Inhibition of Chk1 with the small molecule inhibitor V158411 induces DNA damage and cell death in an unperturbed S-phase. | Wayne, J., et al. 2016. Oncotarget. 7: 85033-85048. PMID: 27829224
- G2-checkpoint targeting and radiosensitization of HPV/p16-positive HNSCC cells through the inhibition of Chk1 and Wee1. | Busch, CJ., et al. 2017. Radiother Oncol. 122: 260-266. PMID: 27939202
- Synthetic Lethality Interaction Between Aurora Kinases and CHEK1 Inhibitors in Ovarian Cancer. | Alcaraz-Sanabria, A., et al. 2017. Mol Cancer Ther. 16: 2552-2562. PMID: 28847989
- CHK1 inhibition sensitizes pancreatic cancer cells to gemcitabine via promoting CDK-dependent DNA damage and ribonucleotide reductase downregulation. | Liang, M., et al. 2018. Oncol Rep. 39: 1322-1330. PMID: 29286153
- Targeting the cell cycle in head and neck cancer by Chk1 inhibition: a novel concept of bimodal cell death. | van Harten, AM., et al. 2019. Oncogenesis. 8: 38. PMID: 31209198
- A screening-based approach identifies cell cycle regulators AURKA, CHK1 and PLK1 as targetable regulators of chondrosarcoma cell survival. | de Jong, Y., et al. 2019. J Bone Oncol. 19: 100268. PMID: 31832331
- The phosphorylation of CHK1 at Ser345 regulates the phenotypic switching of vascular smooth muscle cells both in vitro and in vivo. | Xin, C., et al. 2020. Atherosclerosis. 313: 50-59. PMID: 33027721
- Topsentinol L Trisulfate, a Marine Natural Product That Targets Basal-like and Claudin-Low Breast Cancers. | El-Chaar, NN., et al. 2021. Mar Drugs. 19: PMID: 33477536
- Chk1 and the Host Cell DNA Damage Response as a Potential Antiviral Target in BK Polyomavirus Infection. | Hainley, LE., et al. 2021. Viruses. 13: PMID: 34372559
Inhibitor of:
C17orf53, Chk1, FAAP24, G6Pase-β, NBS1, REV1, SERTAD3, TIPIN, TRABID, and Treslin.Activator of:
Nibrin, and TLK2.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
LY2603618, 5 mg | sc-364526 | 5 mg | $214.00 | |||
LY2603618, 50 mg | sc-364526A | 50 mg | $1809.00 |